Oculis is a clinical-stage biopharmaceutical company focused on treatments for eye diseases. Its pipeline centers on ophthalmic drug candidates, including formulations intended for topical or other eye-targeted delivery. The company aims at conditions of the front and back of the eye where there remains unmet medical need, rather than selling commercial eye-care products at scale today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -33.2 | — |
| Q2 2025 | 0 | — | -25.4 | — |
| Q3 2025 | 0 | — | -16.9 | — |
| Q4 2025 | 0 | — | -23.5 | — |
| Q1 2026 | 0 | — | -28.9 | — |
| Q2 2026 | 0 | — | -10 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Gores Holdings XI, Inc. (GHXI), Kamada Ltd. (KMDA), NRC Health (NRC), Blue Moon Metals Inc. (BMM), Charming Medical Limited (MCTA), Allot Ltd. (ALLT)